University of Michigan researcher will lead first human trial of using stem cells to treat ALS
University of Michigan neurologist Dr. Eva L. Feldman will be the principal investigator for the first human clinical trial of a stem cell treatment for ALS, the fatal neurodegenerative disease also known as Lou Gehrig's disease. Neuralstem Inc., a Rockville, Md., biotechnology company, received U.S. Food and Drug Administration approval to try the drug for safety.